{
    "abstract": "The apelin receptor is a potential target in the treatment of heart failure and pulmonary arterial hypertension where levels of endogenous apelin peptides are reduced but significant receptor levels remain. Our aim was to characterise the pharmacology of a modified peptide agonist, MM202, designed to have high affinity for the apelin receptor and resistance to peptidase degradation and linked to an anti-serum albumin domain antibody (AlbudAb) to extend half-life in the blood. In competition, binding experiments in human heart MM202-AlbudAb (pK",
    "authors": [
        {
            "affiliation": "Experimental Medicine and Immunotherapeutics, Centre for Clinical Investigation, Addenbrooke's Hospital, University of Cambridge, Cambridge, UK.",
            "firstname": "Cai",
            "initials": "C",
            "lastname": "Read"
        },
        {
            "affiliation": "Experimental Medicine and Immunotherapeutics, Centre for Clinical Investigation, Addenbrooke's Hospital, University of Cambridge, Cambridge, UK.",
            "firstname": "Peiran",
            "initials": "P",
            "lastname": "Yang"
        },
        {
            "affiliation": "Experimental Medicine and Immunotherapeutics, Centre for Clinical Investigation, Addenbrooke's Hospital, University of Cambridge, Cambridge, UK.",
            "firstname": "Rhoda E",
            "initials": "RE",
            "lastname": "Kuc"
        },
        {
            "affiliation": "Experimental Medicine and Immunotherapeutics, Centre for Clinical Investigation, Addenbrooke's Hospital, University of Cambridge, Cambridge, UK.",
            "firstname": "Duuamene",
            "initials": "D",
            "lastname": "Nyimanu"
        },
        {
            "affiliation": "Experimental Medicine and Immunotherapeutics, Centre for Clinical Investigation, Addenbrooke's Hospital, University of Cambridge, Cambridge, UK.",
            "firstname": "Thomas L",
            "initials": "TL",
            "lastname": "Williams"
        },
        {
            "affiliation": "The Centre for Molecular Informatics, Department of Chemistry, University of Cambridge, Cambridge, UK.\nComputational and Systems Medicine, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK.",
            "firstname": "Robert C",
            "initials": "RC",
            "lastname": "Glen"
        },
        {
            "affiliation": "GlaxoSmithKline, Stevenage, UK.",
            "firstname": "Lucy J",
            "initials": "LJ",
            "lastname": "Holt"
        },
        {
            "affiliation": "GlaxoSmithKline, Stevenage, UK.",
            "firstname": "Haren",
            "initials": "H",
            "lastname": "Arulanantham"
        },
        {
            "affiliation": "Severn Biotech Ltd, Kidderminster, UK.",
            "firstname": "Andrew",
            "initials": "A",
            "lastname": "Smart"
        },
        {
            "affiliation": "Experimental Medicine and Immunotherapeutics, Centre for Clinical Investigation, Addenbrooke's Hospital, University of Cambridge, Cambridge, UK.",
            "firstname": "Anthony P",
            "initials": "AP",
            "lastname": "Davenport"
        },
        {
            "affiliation": "Experimental Medicine and Immunotherapeutics, Centre for Clinical Investigation, Addenbrooke's Hospital, University of Cambridge, Cambridge, UK.",
            "firstname": "Janet J",
            "initials": "JJ",
            "lastname": "Maguire"
        }
    ],
    "conclusions": null,
    "copyrights": "\u00a9 2019 The Authors. Basic & Clinical Pharmacology & Toxicology published by John Wiley & Sons Ltd on behalf of Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society).",
    "doi": "10.1111/bcpt.13227",
    "journal": "Basic & clinical pharmacology & toxicology",
    "keywords": [
        "AlbudAb",
        "G protein-coupled receptor",
        "apelin",
        "cardiovascular",
        "in vivo"
    ],
    "methods": null,
    "publication_date": "2019-03-23",
    "pubmed_id": "30901161",
    "results": null,
    "title": "Apelin peptides linked to anti-serum albumin domain antibodies retain affinity in vitro and are efficacious receptor agonists in vivo.",
    "xml": "<Element 'PubmedArticle' at 0x788502a12a70>"
}